Kistler-Tiffany Companies’s Sarepta Therapeutics SRPT Stock Holding History

Kistler-Tiffany Companies’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$105K	Hold	920	–	–	0.02%	389
2023 Q1	$127K	Sell	920 -90	-9%	-$11.7K	0.02%	319
2022 Q4	$131K	Hold	1,010	–	–	0.03%	313
2022 Q3	$112K	Hold	1,010	–	–	0.03%	267
2022 Q2	$76K	Buy	1,010 +70	+7%	+$5.15K	0.02%	324
2022 Q1	$73K	Buy	940 +55	+6%	+$4.21K	0.01%	344
2021 Q4	$80K	Buy	885 +105	+13%	+$8.98K	0.02%	322
2021 Q3	$72K	Buy	780 +365	+88%	+$28.1K	0.02%	321
2021 Q2	$32K	Buy	+415	New	+$31.5K	0.01%	427

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kistler-Tiffany Companies's SRPT Position: Q2 2023 in Review

Kistler-Tiffany Companies held its Sarepta Therapeutics (SRPT) position steady in Q2 2023 at 920 shares worth $105K. The position accounts for 0.02% of the portfolio, ranked #389.

Kistler-Tiffany Companies first reported a position in SRPT in Q2 2021 and has held it in 9 quarters since. The position peaked at $131K in Q4 2022. 405 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

Kistler-Tiffany Companies held 920 shares of Sarepta Therapeutics worth $105K as of Q2 2023.
Kistler-Tiffany Companies left its Sarepta Therapeutics share count unchanged in Q2 2023.
Sarepta Therapeutics made up 0.02% of Kistler-Tiffany Companies's portfolio in Q2 2023, its #389 holding.
Kistler-Tiffany Companies first reported a position in Sarepta Therapeutics in Q2 2021 and has held it in 9 quarters since.
Kistler-Tiffany Companies's Sarepta Therapeutics position peaked at $131K in Q4 2022.
405 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on Kistler-Tiffany Companies's 13F filing for Q2 2023, filed 1 Aug 2023.